Research
The Division of Pediatric Endocrinology and Diabetes at Stanford is actively involved in clinical research. If you are interested in being contacted about future studies, please complete the Patient List Research Consent Form. Once completed and submitted, the information you provide will be added to our database of potential research participants.
Diabetes Studies
Studies Currently Recruiting
Recruitment Database
This Redcap database - a list of all patients who have indicated interest in being contacted for participation in Stanford Diabetes Research (T1D + T2D). https://redcap.link/t1dt2dresearch.
Information
Age:2– 70 years
Main Eligibility Criteria:
-T1D and T2D
-Any device or mode of insulin delivery
-Currently English only
Duration Time for Pt in Study: Any amount
Cross Recruitment OK?: Yes
Contact:
PI: Darrell Wilson, MD
Lead CRC: Sarah Hanes sjhanes@stanford.edu
Pathway to Prevention (TrialNet)
Phase 1 Screening: testing for presence of diabetes related autoantibodies. Phase 2 Monitoring: Annual retesting if one autoantibody is positive; Semi-annual study visits if 2 or more autoantibodies are positive. Potential entry into T1D prevention studies.
Information
Age:2.5 – 45 years
Main Eligibility Criteria:
-Relatives of patients with T1D
-English and Spanish Speakers
-Please discuss subjects with PI first
Duration Time for Pt in Study: Screening: 1 visit Positive autoantibodies – See summary at right
Cross Recruitment OK?: Yes
Contact:
PI: Priya Prahalad, MD, PhD
Darrell Wilson, MD
Lead CRC:
Karen Barahona karenbb@stanford.edu
Low Dose ATG
A 2:1 randomized clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. Subjects receive either ATG or placebo in 2 infusions (overnight hospital stay), then come for F/U.
Information
Age:12-35 years
Main Eligibility Criteria:
-Stage 2 at Risk Subjects
-Must have at least two of the high-risk markers
-Abnormal glucose tolerance
Duration Time for Pt in Study: At least 24 Months
Cross Recruitment OK?: Contact PI
Contact:
PI: Priya Prahalad, MD, PhD
Darrell Wilson, MD
Lead CRCs:
Karen Barahona karenbb@stanford.edu
Trudy Esrey, RD, CDE; tesrey@stanford.edu
DiabetesWise for Exercise
The Aim of this project is to make it easier for people with diabetes and their healthcare providers (HCPs) to access and utilize vetted, helpful exercise and physical activity (PA) guidance.
Information
Age:10 – 80 years
Main Eligibility Criteria:
-T1D and T2D
-English or Spanish Speaking
-Any Insurance
-On any Diabetes Technology
Duration Time for Pt in Study: 6 months
Cross Recruitment OK?: No
Contact:
PI: Dessi Zaharieva
Lead Project Manager: Lauren Figg lefigg@stanford.edu
RELAY
A trial testing sequential therapy with Rituximab-pvvr (weekly infusions X4, no placebo), then weekly SQ abatacept or placebo injections at home X 20 months. Determining if Ritux followed by abatacept improves AUC CPeptide compared to Rituximab alone. Follow up Q 6 mos. X2 yrs.
Information
Age: 8-45 years
Main Eligibility Criteria:
-New Onset within 100 days of diagnosis
-English or Spanish Speaking
-Compensation for study-related travel provided.
Duration Time for Pt in Study: 48 Months: 24 months of treatments, 24 months of follow up
Cross Recruitment OK?: Observational or Psychological/Behavioral studies only
Contact:
PI:Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRCs:
Trudy Esrey tesrey@stanford.edu
JAKPOT TN31
Trial testing 2 JAK inhibitors, abrocitinib and ritlecitinib in new onset T1D participants. Randomized in a 1:1:1 allocation with placebo as 3rd arm. 12 months of active treatment (daily oral medication) with drug or placebo, then 12 months of F/U.
Information
Age: 12-35 years
Main Eligibility Criteria:
-New Onset T1D within 100 days of diagnosis
-English or Spanish Speaking
-Compensation for study-related travel provided.
Duration Time for Pt in Study: 24 Months: 12 months of treatment; 12 months of follow up
Cross Recruitment OK?: No
Contact:
PI: Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRCs:
Trudy Esrey tesrey@stanford.edu
Building the Evidence to Address Disparities in Type 1 Diabetes (BEAD-T1D)
Building the Evidence to Address Disparities in Type 1 Diabetes - We will utilize surveys and focus groups to identify barriers and promoters of diabetes technology use in youth with public insurance and T1D followed by an advisory board to develop an intervention.
-Duration: 1 year
-Main Eligibility Criteria: youth age <12, with public insurance, parent study (no youth participation)
To learn more about this study, please contact Ricardo Medina Penaranda at 661-616-8415 or ricarmp@stanford.edu.
DIAGNODE-3 STUDY
Trial testing an investigational drug, Diamyd® (rhGAD65), to determine its ability to preserve the body’s insulin-producing capacity by halting or delaying the autoimmune attack on the beta cells. Randomized 2:1 study agent: placebo. Screening visits followed by 3 monthly injections of drug or placebo, then 22 months of F/U.
Information
Age: 12-28 years
Main Eligibility Criteria:
-New Onset T1D within 6 months of diagnosis
-Presence of HLA DR3-DQ2 haplotype (you will be tested for this)
-English or Spanish Speaking
-Compensation for study-related travel provided.
Duration Time for Pt in Study: 26 months: 3 Screening run-in visits, 3 injections over 2 months, 22 months of follow up visits.
Cross Recruitment OK?: No
Contact:
PI: Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRC:
Trudy Esrey tesrey@stanford.edu
Other Endocrine Studies
PWS-Carbetocin Nasal Spray
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
-Duration: 12 weeks long
-Main Eligibility Criteria: 5-30 yrs
-English and Spanish speaking
PI: Diane Stafford, MD
Lead CRC:
Alondra Loyola aloyola1@stanford.edu
PWS-Open Label Continuation phase of Carbetocin Nasal Spray
A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Duration: 3 years
-Main Eligibility Criteria: 5-30 yrs
-English and Spanish speaking
PI: Diane Stafford, MD
Lead CRC:
Alondra Loyola aloyola1@stanford.edu
PWS-Non-Invasive Vagus Nerve Stimulation
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS (VNS4PWS) in Prader-Willi Syndrome
Duration: 2 years in length including the Open Label Extension
-Main Eligibility Criteria: 10-40 yrs
-English speaking
PI: Diane Stafford, MD
Lead CRC:
Alondra Loyola aloyola1@stanford.edu
Mission Statement
Our mission is to innovate basic, translational, and clincial research in endocrinology and diabetes grounded in the principles of excellence and equity to advance scientific knowledge and improve the lives of all.
Stanford Diabetes Research Center
The SDRC promotes the teaching and training goals of Stanford University by training the next generation of investigators and leaders of diabetes research and care.
Basic Research
The aim of our basic science program is to elucidate the role of the endocrine system in both health and the development of diseases. Through this work, we hope to increase our understanding of the important physiological processes that are controlled by hormones and how alterations in hormone levels perturb the body’s homeostasis and cause disease in people. Our goal is to apply discoveries we make in the laboratory toward the development of novel therapeutics for a variety of illnesses that affect children.
You can read more about the work of faculty member Anna Gloyn and her team.
Research Database
Join our database to receive study recruitment emails. Click the button below.